 A FDG-PETMR imaging study will be performed at a second screening visit visit 2 to assess for the presence of arterial, plaque and joint inflammation. A serum pregnancy test will be drawn and confirmed to be negative prior to imaging for female subjects of childbearing potential. Acceptability for study participants will be confirmed on the basis of a tissue-to-background ratio TBR of greater than or equal to 1.7 in qualifying vessel calculated using the mean of the maximum SUV as measured from FDG-PETMR imaging. Participants who meet clinical and imaging eligibility criteria will be enrolled into the study visit 3. Subjects will receive first dose of tocilizumab subcutaneously, on subsequent weeks, subjects will be instructed to self-administer tocilizumab at a dose of 162mg every week for a 12 week period. 4 weeks post-initiation, participants will return for a clinical safety follow-up visit 4. Final evaluation will include physical exams, clinical assessments and carotid IMT test. A second FDG-PETMR imaging session will take place 12 weeks post-administration visit 5. 